ReNeuron Group Plc (LON:RENE) fell 2% during mid-day trading on Thursday . The stock traded as low as GBX 120 ($1.57) and last traded at GBX 124 ($1.62), 9,752 shares were traded during mid-day trading. A decline of 66% from the average session volume of 28,700 shares. The stock had previously closed at GBX 126.50 ($1.65).
The company has a market cap of $39.00 million and a P/E ratio of -2.71. The firm’s 50-day moving average price is GBX 156.34 and its 200-day moving average price is GBX 221.42.
ReNeuron Group Company Profile (LON:RENE)
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.
Featured Story: Why do companies issue convertible shares?
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.